- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Title X Decision; Missouri Abortion Clinic Defies State; WHO Removes Opioid Guidelines
A federal appeals court has ruled that the Trump administration's family planning rule can go into effect as several lawsuits over the rule play out; Missouri's only abortion clinic will defy the state by refusing to perform a required pelvic exam days before an abortion; the World Health Organization (WHO) has removed 2 guidelines on opioids following allegations of industry influence.
Trump Family Planning Rule Will Go Into Effect
Missouri Abortion Clinic Won’t Comply With Pelvic Exam Requirement
WHO Removes Opioid Guidelines Following Claims of Industry Influence
The 9th US Circuit Court of Appeals ruled that the Trump administration’s family planning restrictions can go into effect as various lawsuits over the rule play out, reported Politico. The panel of 3 judges granted the administration’s request to lift national injunctions ordered by lower federal courts in Oregon and Washington state, as well as a statewide injunction in California. The panel said that the administration will likely win the legal battle over the Title X family planning program because the Supreme Court upheld similar rules nearly 30 years ago, although they were then reversed by the Clinton administration before taking effect.Missouri’s only abortion clinic said it will defy the state by refusing to perform a required pelvic exam days before an abortion, calling the exam requirement “disrespectful and dehumanizing.” According to The Associated Press, a Planned Parenthood spokeswoman confirmed that as of Thursday, the St. Louis clinic no longer performs the exam during a consultation at least 72 hours before an abortion. The spokeswoman also said that the exam is not required by state law but is an intrusive health department regulation.After US lawmakers alleged that 2 of the World Health Care Organization’s (WHO’s) prescription guidelines for opioids were influenced by the pharmaceutical industry, WHO has withdrawn the guidelines. According to The Wall Street Journal, the organization said it was discontinuing the guidelines “in light of new scientific evidence” and that the move will also “address any issues of conflicts of interest of the experts that have been raised.” The 2 sets of guidelines focused on the availability and accessibility of controlled medicine and the treatment for persisting pain in children with illnesses.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
